Predict your next investment

HEALTHCARE | Biotechnology
interceptpharma.com

See what CB Insights has to offer

Founded Year

2002

Stage

PIPE | IPO

Total Raised

$121M

Market Cap

0.52B

Stock Price

17.00

Revenue

$0000 

About Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe, and Canada.

Intercept Pharmaceuticals Headquarter Location

10 Hudson Yards 37th Floor

New York, New York, 10013,

United States

844-782-4278

Latest Intercept Pharmaceuticals News

Primary Biliary Cholangitis (PBC) Treatment Market to Witness Excellent Revenue Growth, Overview, Emerging Trends and Forecast by 2027

Jan 18, 2022

Search jobs 18-Jan-2022 Primary Biliary Cholangitis (PBC) Treatment Market to Witness Excellent Revenue Growth, Overview, Emerging Trends and Forecast by 2027 Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally diagnosed during routine blood examination which presents symptoms like fatigue, pertussis, and right upper quadrant discomfort. In initial examination finding the disease is normal, as the disease advances present symptoms of liver cirrhosis. The hallmark of primary biliary cirrhosis is the presence of ant mitochondrial antibodies (AMAs) in the blood. Medical management of primary biliary cirrhosis mainly done to slow the symptom progression and to alleviate the symptoms. Gain complete access to the report @ https://www.futuremarketinsights.com/reports/primary-biliary-cholangitis-pbc-treatment-market Primary Biliary Cholangitis Treatment Market: Drivers and Restraints Global primary biliary cholangitis treatment market is expected to drive by highly unmet medical need owing lack of definitive treatment, advanced diagnostic process coupled rising awareness among healthcare professionals and patients alike across the globe. The Incidence and prevalence of primary biliary cholangitis vary geographically, ranging from 0.7 to 49 and 6.7 to 402 per million, respectively. The factors currently contributing to the revenue growth of the primary biliary cholangitis treatment market is increasing incidence and prevalence of the disease, increased exposure to environmental triggers to immune system such as pesticides. Furthermore, lifestyle changes like smoking, alcoholism, and obesity are expected to drive the market for primary biliary cholangitis treatment over the forecast period. Global primary biliary cholangitis treatment market hindered by the lack of definitive treatment for the disease and late diagnosis of the disease led to treatment deprivation to the patient. The market restrained by dearth of epidemiology data which helps to assess the product access and availability in various geographies which are expected to hinder market revenue growth of primary biliary cholangitis treatment over the forecast period Primary Biliary Cholangitis Treatment Market: Overview Global primary biliary cholangitis treatment market is witnessing significant changes due to recent approval of UDCA by several regulatory authorities across the globe. In May 2016, the FDA approved obeticholic acid in combination with UDCA for primary biliary cholangitis (PBC) in adult patients with an inadequate response to UDCA. U.K’s NICE (National Institute for Health and Care Excellence) and European Commission granted the market authorization for Ocaliva (obeticholic acid) form Intercept Pharmaceuticals, Inc. in the year 2017 and 2016 respectively. To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3773 Primary Biliary Cholangitis Treatment Market: Region-wise Outlook Geographically, Primary biliary cholangitis treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Western Europe will remain key markets for primary biliary cholangitis treatment products due to increased regulatory approvals for treatment options, increasing awareness among patient advocacy groups regarding primary biliary cholangitis helps to maintain larger market share in the globalprimary biliary cholangitis treatment market by the regions. Asia Pacific is anticipated to present better growth opportunity owing to large untapped market, increasing out of pocket expenditure, and growing government’s interventions for improving healthcare infrastructure in the region. Primary Biliary Cholangitis Treatment Market: Key Players Some of the players in the global primary biliary cholangitis treatment market are Intercept Pharmaceuticals, Inc., Actavis, Inc., Teva Pharmaceuticals Inc., Epic Pharma, LLC, Mylan Pharmaceuticals Inc., and Axcan Scandipharm Inc.  to name a few. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications. The report covers exhaustive analysis on: Market Segments Latin America (Mexico, Brazil and Rest of Latin America) Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg and Rest of Western Europe) Eastern Europe (Poland, Russia and Rest of Eastern Europe) Asia Pacific (China, India, ASEAN, Australia & New Zealand) Japan Middle East and Africa (GCC, S. Africa, and Rest of MEA) The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Primary Biliary Cholangitis Treatment Market: Segmentation Global primary biliary cholangitis treatment market has been segmented on the basis of treatment type, end user and Region. Based on the treatment type, the global primary biliary cholangitis treatment market is segmented into the following: For Treatment

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Intercept Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intercept Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Intercept Pharmaceuticals Patents

Intercept Pharmaceuticals has filed 63 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Intracellular receptors
  • Hepatology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/23/2016

7/27/2021

Transcription factors, Intracellular receptors, G protein coupled receptors, Peptide hormones, Human proteins

Grant

Application Date

9/23/2016

Grant Date

7/27/2021

Title

Related Topics

Transcription factors, Intracellular receptors, G protein coupled receptors, Peptide hormones, Human proteins

Status

Grant

Intercept Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intercept Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.